JNJ — Johnson & Johnson

Johnson & Johnson Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Sales: Worldwide sales reached $24 billion, reflecting a 5.4% operational growth despite a 640 basis point headwind from the loss of exclusivity of STELARA.
• Net Earnings: Reported net earnings were $5.2 billion, with diluted earnings per share (EPS) of $2.12, up from $1.11 a year ago. Adjusted net earnings were $6.8 billion, leading to an adjusted diluted EPS of $2.80, a 15.7% increase compared to 2024.
• Segment Performance:
  • Innovative Medicine: Sales of $15 billion, up 5.3%, with significant contributions from DARZALEX and TREMFYA.
  • MedTech: Sales of $8.4 billion, up 5.6%, driven by cardiovascular and surgical segments.

2. Strategic Updates and Business Highlights:

• Innovative Medicine Growth: Achieved double-digit growth across 11 brands, with notable performances from CARVICTI (up 81.4%) and TREMFYA (up 40.1%).
• MedTech Developments: Announced the planned separation of the Orthopaedics business to sharpen focus on high-growth areas like cardiovascular and robotic surgery.
• Pipeline Progress: Continued advancements in oncology, immunology, and neuroscience, with several new product launches expected to drive future growth.
• Acquisitions: Completed over 60 strategic deals in the past 18 months, enhancing the product portfolio.

3. Forward Guidance and Outlook:

• 2025 Guidance: Increased operational sales growth guidance to 4.8% to 5.3%, with an adjusted EPS forecast of $10.85, reflecting strong confidence in the pipeline and market position.
• 2026 Outlook: Anticipated continued growth driven by new product launches and a strong pipeline, with expectations for sales growth exceeding 5%.

4. Bad News, Challenges, or Points of Concern:

• STELARA Decline: Experienced a 42% decline in STELARA sales due to biosimilar competition, which is expected to continue impacting overall sales.
• Tax Rate Increase: Effective tax rate rose to 31.2%, influenced by a one-time remeasurement of deferred tax balances.
• MedTech Margin Pressure: MedTech margins declined from 24.1% to 21% due to macroeconomic factors and increased costs.

5. Notable Q&A Insights:

• Orthopaedics Spin-off: Management emphasized that the separation is aimed at enhancing operational focus and capitalizing on growth opportunities in orthopaedics, which is a $50 billion market.
• Market Dynamics: Executives discussed the competitive landscape and ongoing dialogues with the administration regarding healthcare policies, including potential MFN agreements.
• Growth Discrepancies: Analysts raised questions about the disconnect between internal growth expectations and consensus estimates for 2026, with management expressing confidence in exceeding the 5% growth target.
• Product Positioning: Discussion on the positioning of icotrokinda relative to TREMFYA highlighted the potential for both products to thrive in the market due to their unique profiles and high unmet needs.

Overall, Johnson & Johnson reported a strong quarter with solid growth across its segments, while also addressing challenges related to competition and regulatory changes. The company is optimistic about its future growth trajectory, driven by innovation and strategic focus.